NCT06238752View on ClinicalTrials.gov

First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

March 1, 2023

Study Completion Date

January 1, 2024

Conditions
Advanced Gastric Adenocarcinoma
Interventions
DRUG

Apatinib Combined With Tislelizumab and Chemotherapy

apatinib (250 mg, qd, d1-14), tislelizumab(200 mg d1), and oxaliplatin (130 mg/m2, d1) plus oral capecitabine (1000 mg/m2, bid, d1-14) every 3 weeks

Trial Locations (1)

430060

Renmin hosptial of Wuhan University, Wuhan

All Listed Sponsors
lead

Renmin Hospital of Wuhan University

OTHER

NCT06238752 - First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC | Biotech Hunter | Biotech Hunter